Belantamab mafodotin-blmf (Blenrep; GlaxoSmithKline) is the first in its class anti-BCMA therapy to gain FDA approval.
Lynnette Henshaw, PharmD
Advertisement
Articles by Lynnette Henshaw, PharmD
Advertisement
Latest Updated Articles
First-in-Class Approved Anti-BCMA Therapy: Belantamab Mafodotin-blmfPublished: December 22nd 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Breaking News: CVS Buys Rite Aid, Bartell Drugs
2
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
3
FDA Approves 1-Minute HIV Self-Test
4
Young Women With Symptomatic Long COVID At Higher Risk of POTS
5
